These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2458744)

  • 1. Lymphokine-activated killer cells: analysis of their anti-tumour efficacy in vitro and in vivo.
    Hiserodt JC; Chambers WH; Herberman RB
    Ann Inst Pasteur Immunol; 1988; 139(4):466-78. PubMed ID: 2458744
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on lymphokine activated killer cells in the rat: analysis of precursor and effector cell phenotype and relationship to natural killer cells.
    Hiserodt JC; Vujanovic NL; Reynolds CW; Herberman RB; Cramer DV
    Prog Clin Biol Res; 1987; 244():137-46. PubMed ID: 2958869
    [No Abstract]   [Full Text] [Related]  

  • 3. Lymphokine-activated killer cells. Induction and function.
    Grimm EA; Owen-Schaub LB; Loudon WG; Yagita M
    Ann N Y Acad Sci; 1988; 532():380-6. PubMed ID: 3140701
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of soluble cytotoxic factors in lymphokine-activated killer cell (LAK)-mediated cytotoxicity.
    Hiserodt JC; Chambers WH
    Ann N Y Acad Sci; 1988; 532():395-404. PubMed ID: 3052213
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effects of interleukin-2 and lymphokine-activated killer cells on cell cultures and on transplanted tumors (nude mouse) of human pancreatic carcinomas].
    Kühl JS; Klapdor R; Bahlo M; Arps H; Dietel M; Mohr M
    Beitr Infusionther Klin Ernahr; 1987; 18():261-5. PubMed ID: 3501948
    [No Abstract]   [Full Text] [Related]  

  • 6. Production of lymphokine-activated lymphocytes. Lysis of human head and neck squamous cell carcinoma cell lines.
    Alessi DM; Hutcherson RW; Mickel RA
    Arch Otolaryngol Head Neck Surg; 1989 Jun; 115(6):725-30. PubMed ID: 2785809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of serum-free culture medium in the generation of lymphokine activated killer cells.
    Muul LM; Nason-Burchenal K; Hyatt C; Schwarz S; Slavin D; Director EP; Rosenberg SA
    J Immunol Methods; 1987 Dec; 105(2):183-92. PubMed ID: 3693906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of cancer with lymphokine-activated killer cells and interleukin-2.
    N Engl J Med; 1987 Oct; 317(15):961-3. PubMed ID: 3498120
    [No Abstract]   [Full Text] [Related]  

  • 9. [Lymphokines].
    Okuno K; Hamaoka T
    Gan To Kagaku Ryoho; 1982 Dec; 9(12):2053-64. PubMed ID: 6764096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance.
    Rivoltini L; Gambacorti-Passerini C; Supino R; Parmiani G
    Int J Cancer; 1989 May; 43(5):880-5. PubMed ID: 2714894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice.
    Andriole GL; Mulé JJ; Hansen CT; Linehan WM; Rosenberg SA
    J Immunol; 1985 Nov; 135(5):2911-3. PubMed ID: 3876368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic uses of interleukin-2 and lymphokine-activated killer (LAK) cells.
    Richards JM
    Blood Rev; 1989 Jun; 3(2):110-9. PubMed ID: 2673443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer, lymphokine-activated killer and interferon-gamma producing activities of peripheral blood- and regional lymph node-mononuclear cells in 23 cases of colorectal cancer.
    Matsunaga H; Kuwahara Y; Kusugami K; Morise K; Shimokata K
    Gastroenterol Jpn; 1988 Oct; 23(5):527-33. PubMed ID: 3145895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired lymphokine-activated killer-cell activity in patients with hypogammaglobulinaemia.
    Gao L; Malkovský M; Webster AD; Asherson GL
    Lancet; 1985 Aug; 2(8450):340. PubMed ID: 2862509
    [No Abstract]   [Full Text] [Related]  

  • 15. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.
    Fisher RI; Coltman CA; Doroshow JH; Rayner AA; Hawkins MJ; Mier JW; Wiernik P; McMannis JD; Weiss GR; Margolin KA
    Ann Intern Med; 1988 Apr; 108(4):518-23. PubMed ID: 3258138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.
    Mulé JJ; Smith CA; Rosenberg SA
    J Exp Med; 1987 Sep; 166(3):792-7. PubMed ID: 3498002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyst fluid of glioma does not inhibit the killing action of lymphokine-activated killer (LAK) cells in vitro.
    Jääskeläinen J; Kalliomäki P; Paetau A; Saksela E; Timonen T
    Acta Neurochir (Wien); 1988; 91(1-2):73-8. PubMed ID: 3394550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 2 and lymphokine-activated killer cells in the treatment of childhood primary hepatocellular carcinoma--a preliminary report.
    Hsieh KH; Chang JS; Wu HL; Chu CT
    Asian Pac J Allergy Immunol; 1987 Jun; 5(1):13-6. PubMed ID: 3040030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are lymphokine activated killer cells a possible form of leukaemia immunotherapy?
    Tratkiewicz JA; Szer J; Boyd RL
    Adv Exp Med Biol; 1988; 237():447-50. PubMed ID: 3254057
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of lymphokine-activated killer cells as mediators of veto and natural suppression.
    Azuma E; Kaplan J
    J Immunol; 1988 Oct; 141(8):2601-6. PubMed ID: 3171179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.